Catalog No.
RHF97202
Species reactivity
Human
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Isoform 3 of Dystonin, 230 kDa bullous pemphigoid antigen, 230/240 kDa bullous pemphigoid antigen, Bullous pemphigoid antigen 1, BPA, Bullous pemphigoid antigen, Dystonia musculorum protein, Hemidesmosomal plaque protein, DST, BP230, BP240, BPAG1, DMH, DT, KIAA0728
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q03001-3
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAb2260
[Not Available]., PMID:40532789
Aberrant glycosylation patterns as potential biomarkers for diagnosis and disease progression in bullous pemphigoid., PMID:40491922
Complete Resolution of Atypical Paraneoplastic Pemphigus Following Treatment With Dupilumab., PMID:40264631
Unraveling the Link Between Bullous Pemphigoid and Neurological Disease: A Single-center Study of 257 Patients., PMID:40204134
Localization of Lesions in Autoimmune Blistering Diseases Is Independent of Site-Specific Target Antigen Expression., PMID:40003627
Periostin in Bullous Pemphigoid: A Potential Biomarker of Disease Activity and Severity., PMID:39989295
Bullous pemphigoid., PMID:39979318
Diagnostic methods and strategies for autoimmune bullous diseases., PMID:39930606
Correlation of BP180, BP230, and type VII collagen antibody titers in serum, blister fluid, erosion, and saliva in pemphigoid diseases., PMID:39916594
Linear IgA bullous dermatosis-a fifty year experience of Warsaw Center of bullous diseases., PMID:39877369
Clinical characteristics of bullous pemphigoid patients of different ages and the possible mechanism., PMID:39821084
Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230., PMID:39676877
Use of multivariant enzyme-linked immunosorbent assay (ELISA) in the diagnosis of autoimmune bullous disorders in a resource-limited setting: A single-center experience., PMID:39635793
Ocular Mucous Membrane Pemphigoid Demonstrates a Distinct Autoantibody Profile from Those of Other Autoimmune Blistering Diseases: A Preliminary Study., PMID:39584991
The "entanglement" between bullous pemphigoid and diabetes mellitus: a comprehensive review and expert recommendations., PMID:39521622
Clinical manifestation variability of bullous pemphigoid., PMID:39487837
A case of mucous membrane pemphigoid solely with IgA anti-BP230 antibodies detected by immunoblotting using normal human epidermal extracts., PMID:39435999
Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review)., PMID:39425892
Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis., PMID:39356527
The possible and intriguing relationship between bullous pemphigoid and melanoma: speculations on significance and clinical relevance., PMID:39267741
Polarization of circulating follicular helper T cells correlates with bullous pemphigoid severity., PMID:39255051
The Role of Serology in the Diagnosis of Ocular Predominant Mucous Membrane Pemphigoid and the Search for an Ocular-Specific Autoantigen., PMID:39241171
Occurrence of Bullous Pemphigoid in a Longstanding Case of Rheumatoid Arthritis in an Indian Patient: A Rare Association., PMID:38807846
Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity., PMID:38582700
Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study., PMID:38389191
Expression of Serum Anti-BP180/230 Antibodies in Bullous Pemphigoid Patients Combined with Nervous System Diseases and Relevant Factor Analysis., PMID:38342861
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update., PMID:38157140
From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid., PMID:38069109
Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches., PMID:37897588
The Eotaxin-1/CCR3 Axis and Matrix Metalloproteinase-9 Are Critical in Anti-NC16A IgE-Induced Bullous Pemphigoid., PMID:37672029
Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches., PMID:37614956
Evaluation of Dupilumab in Patients With Bullous Pemphigoid., PMID:37531116
Eosinophils, Basophils, and Neutrophils in Bullous Pemphigoid., PMID:37509055
Case Report: Prurigo nodularis-like linear IgA/IgG bullous dermatosis: a case report and literature review., PMID:37325615
Evaluation of ELISA BP180 and BP230 Autoantibodies in Blister Fluid and Serum in the Diagnosis of Bullous Pemphigoid., PMID:37151247
Mixed muco-cutaneous pemphigoid: Clinical and immunological features of 15 cases., PMID:37006294
Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid., PMID:36999962
Research progress of omalizumab in the treatment of bullous pemphigoid., PMID:36971190
Nail abnormalities in subepidermal blistering diseases: a cross-sectional study., PMID:36951363
Interleukin-36 cytokines are overexpressed in the skin and sera of patients with bullous pemphigoid., PMID:36940975
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid., PMID:36937423
Disease Endotypes Predict the Severity of Mucous Membrane Pemphigoid., PMID:36870557
Lichen Planopilaris Pemphigoides: A Novel Bullous Dermatosis Due to Programmed Cell Death Protein-1 Inhibitor Therapy., PMID:36825932
Pilot study investigating BP-180 in extracellular vesicles derived from blister fluid of bullous pemphigoid patients., PMID:36763158
Bullous pemphigoid in a patient with a neuropsychological disorder and a possible novel drug trigger: A case report and review of the literature., PMID:36479274
Utility of the pattern-based approach using BIOCHIP-indirect immunofluorescence in the evaluation of subepidermal bullous disorders., PMID:36444506
What's new in the pathogeneses and triggering factors of bullous pemphigoid., PMID:36412277
Case report: Detection of anti-bullous pemphigoid antigen 180 antibodies in a patient with Behçet's disease., PMID:36341270
A case of dipeptidyl peptidase-4 inhibitor-related anti-BP230-type bullous pemphigoid showing granular C3 dermatosis-like direct immunofluorescence staining., PMID:36301770
Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid., PMID:36259470
For research use only. Not for human or drug use.
